OptiBiotix Health PLC Director's Dealing (3997K)
28 August 2019 - 7:00PM
UK Regulatory
TIDMOPTI
RNS Number : 3997K
OptiBiotix Health PLC
28 August 2019
28 August 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Director's Dealing
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it received notification today that
Frédéric Narbel, a Director of the Company, acquired 17,000
ordinary shares in the Company today, representing 0.02% of the
Company's issued share capital, at a price of 50 pence per
share.
Following the transaction, Mr Narbel is interested in 29,000
ordinary shares in the Company, representing 0.03% of the Company's
issued share capital.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 and the person who arranged
for release of this announcement on behalf of the Company was
Stephen O'Hara, Chief Executive.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
-----------------------------------------------------------------------------------------
a. Name Frédéric André Narbel
--------------------------------------- ------------------------------------------------
2 Reason for notification
--------------------------------------- ------------------------------------------------
a. Position/Status Director of the Company
--------------------------------------- ------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
--------------------------------------- ------------------------------------------------
b. LEI 213800UKYQFT941QHS14
--------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------------------
a. Description of 17,000 ordinary shares of 2p each
the financial
instrument, type
of instrument
ISIN: GB00BP0RTP38
Identification
Code
--------------------------------------- ------------------------------------------------
b. Nature of the Purchase of 17,000 ordinary shares in the
transaction Company
--------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
--------------------------------------- -------------------------
50p 17,000
------------------------- -----------------
e. Date of the transaction 28 August 2019
--------------------------------------- ------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
--------------------------------------- ------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHGIGDIISDBGCI
(END) Dow Jones Newswires
August 28, 2019 05:00 ET (09:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
